L-Glutamine — Body Handbook

Supplements · §515

L-Glutamine

The tub in the supplement aisle promises gut healing, immune protection, and muscle recovery. The trials in healthy people consistently show none of those things — the resistance-training studies are flat, the exercise-immunity hypothesis didn't replicate, and most of an oral dose is eaten by the gut itself before it reaches the bloodstream. There are two real exceptions: sickle cell disease, where it's FDA-approved and earns its place; and a specific kind of stubborn diarrhoea that follows a stomach bug, where one good trial showed a big effect. For everyone else, the honest read is to close the tab and put the money toward something that works.

Decide · Daily Evidence Mixed Chapter Supplements

If you're a healthy adult buying this on a gym-bro recommendation, the trials say you can stop. If you have sickle cell disease, it's real medicine — talk to your doctor, not your supplement shop. If you've been miserable with diarrhoea since a stomach bug a year ago, there's one trial worth bringing up at your next appointment. Cost is trivial; the question isn't the price, it's whether you're paying for anything at all.

Glutamine is the most common loose amino acid floating around your body — about 60% of what's in your muscles and 20% of what's in your blood. Your body makes it on its own, mostly in muscle and lungs, and under normal conditions it makes more than enough. The reason it shows up on supplement shelves at all is what happens in extreme states: a serious burn, sepsis, or a body that's been catabolic for weeks. In those states, demand outstrips supply, and clinicians can sometimes patch it by giving it through an IV. That's the trail of evidence the consumer market is borrowing from.

The two mechanisms that look real on paper:

The gut lining lives on it. The cells that line your small intestine — the ones renewing themselves constantly — burn glutamine instead of glucose. In a petri dish, take it away and the seals between those cells (the tight junctions) literally start to come apart; add it back and they reform Rao & Samak 2012. That's the cleanest mechanistic story for the substance.

Immune cells run on it too. Your white blood cells use glutamine at roughly the same rate as glucose when they're working — multiplying, killing bacteria, mopping up after a workout. After a marathon, your blood glutamine drops about 20% and stays low for hours Castell et al. 1996. The supplement industry took that observation, called it the glutamine hypothesis of exercise immunology, and built a marketing category. The catch is in the next section.

What the trials actually show

This is where the substance splits in two. In a handful of narrow medical populations, the evidence is real. In the population the tub is sold to — healthy people who train and care about recovery — the trials are flat.

Sickle cell disease. A 230-person trial gave patients a weight-based dose of L-glutamine twice a day for nearly a year. Pain crises dropped by about a quarter, and people spent about six and a half fewer days in the hospital over the trial period. That's the trial that got the molecule approved by the FDA in 2017, sold as Endari.

The stubborn-stomach-bug kind of IBS. A second clean trial enrolled 106 adults who'd developed diarrhoea-predominant irritable bowel syndrome after a documented stomach infection and who tested positive for a leaky gut barrier (a lab test that measures whether sugar molecules sneak through the intestinal wall). At 5 grams three times a day for eight weeks, four out of five people on glutamine had a major drop in symptoms, versus one in twenty on placebo.

Healthy lifters and athletes. Here the story falls apart. A 2001 trial put 31 young adults through six weeks of resistance training with either glutamine or a sugar placebo — same lean mass gains, same strength gains, no difference in muscle protein breakdown markers Candow et al. 2001. Adding it to a post-workout protein shake doesn't boost muscle protein synthesis above what the protein alone does Wilkinson et al. 2006. The 2019 round-up of every clinical trial in athletes — performance, body composition, muscle damage, immunity — found nothing significant on any of them Ramezani Ahmadi et al. 2019.

The exercise-immunity hypothesis didn't replicate. The original 1996 marathon study reported fewer self-reported colds in the glutamine arm Castell et al. 1996, and that single result launched the category. Better-controlled follow-up work failed to repeat it — glutamine doesn't restore the drop in salivary antibodies after hard exercise Krzywkowski et al. 2001, and the field's most-cited 2008 review concluded the hypothesis "is not supported by interventional trials" Gleeson 2008.

The very sickest hospital patients. Not where the supplement story usually goes, but worth flagging because it's the high-dose case. A 1,200-person multi-centre trial gave critically ill patients with failing organs both IV and tube-fed glutamine at high doses; six-month death rates were significantly higher in the glutamine arm Heyland et al. 2013. Clinical guidance has walked back from routinely giving it to the sickest ICU patients since.

What the marketing gets wrong

"Your blood glutamine drops after exercise, so you need to replace it." The drop is real. The conclusion doesn't follow. Topping the blood back up doesn't restore immune function or reduce post-workout colds in controlled trials — the dip and the immune effects turn out to be two separate things, both downstream of the workout itself Gleeson 2008.

"It prevents muscle breakdown." True in someone who's been catabolic for weeks after a serious burn or in intensive care. Not true in a healthy person who lifts three times a week and eats enough protein. Whey protein is roughly 5–6% glutamine residues by weight; a normal high-protein diet already delivers around ten grams of glutamine bound up in food. Adding five grams of free powder is a small marginal change against that background, and the trials confirm it doesn't move the needle Wilkinson et al. 2006.

"It heals leaky gut." This is the slippery one. In the narrow trial population — people whose IBS started after a stomach bug and who tested positive on the lab measure of intestinal permeability — yes, the trial showed a big effect Zhou et al. 2019. In the much broader wellness-market sense of "leaky gut" — bloating, fatigue, brain fog, no formal diagnosis — that trial does not transfer. The general "leaky gut syndrome" construct doesn't even have agreed diagnostic criteria. Buying glutamine for vague gut complaints is buying into a borrowed mechanism without a real indication.

"It reaches your muscles." Mostly not. The gut itself is a major glutamine consumer — most of an oral dose gets eaten on the way through, before it ever reaches the bloodstream Gleeson 2008. The dose on the label and the dose your muscles see are different numbers.

Who, if anyone, should consider it

Three populations where the call genuinely changes:

Sickle cell disease. If you or your child has sickle cell, this isn't a gym-shelf decision. It's a real medication called Endari, dosed by weight twice a day, with a phase-3 trial behind it. The conversation is with your haematologist, not your supplement-store clerk. The branded prescription form is what insurance covers — generic bulk powder is the same molecule but you'd be off-label and unsupervised.

Diarrhoea that started after a stomach bug and never really left. If your gut symptoms began after a documented infection — a bad bout of food poisoning, traveller's diarrhoea, a confirmed gastroenteritis — and the diarrhoea-and-cramping has run for months, you're closer to the trial population than most "IBS" patients are. Bring the trial up at your next appointment. Your doctor can also order the leaky-gut lab test (a lactulose/mannitol urine test) that defined who got into the trial — if that's elevated, the eight-week course at five grams three times a day is what the trial protocol looked like.

Everyone else. The healthy lifter, the recreational runner, the person who feels a bit off and is scrolling supplement reviews — the honest call is no. The trials in your population are flat, and the mechanism the marketing leans on doesn't connect to anything your body is actually short on.

If you're going to take it anyway

For the indications above, the doses with trial backing are specific. Anything outside those is unsupported by data — which doesn't mean it'll harm you (it's a remarkably safe molecule at oral doses up to about 30 grams a day in healthy adults Garlick 2001), but you should know you're improvising.

When not to take it

What would actually move the needle

For each thing the supplement is sold to fix, something else has better evidence:

Recovery and muscle preservation after training. Total daily protein at roughly 1.6 grams per kg of body weight, creatine monohydrate (the supplement with the strongest healthy-adult evidence base by a wide margin), enough sleep, and a sane training program. None glamorous. All boring. All work.
"Gut health" without a specific diagnosis. The low-FODMAP diet has the broadest evidence base for general IBS symptoms. Soluble fibre. Treating an actual SIBO or post-infection picture rather than guessing at one.
Immunity around hard training. Sleep is the dominant lever — short sleep predicts post-event respiratory infection far more reliably than glutamine status does. Periodised training load. Adequate calories and protein. Vitamin D if you're deficient.
Sickle cell. Hydroxyurea, voxelotor, and crizanlizumab each have their own indications and evidence base. Endari is one tool, not the whole toolbox.

Cost and where to get it

Bulk L-glutamine powder is a commodity. A one-pound tub runs $15–25 at any sports-nutrition retailer; at the typical five-gram-a-day dose that's roughly three months of supply, or $60 to $100 a year. The molecule is the same whatever brand you pick; the third-party-tested ones cost a few dollars more and are worth it for a daily supplement.

The branded prescription form for sickle cell, Endari, costs orders of magnitude more — list pricing has run into the tens of thousands of dollars per year — but is almost always covered by insurance for the on-label indication. Generic bulk powder is chemically identical but isn't the FDA-approved product, which matters for documentation, insurance reimbursement, and clinical supervision.

What you're paying for if you keep buying it

Not a health stake — the substance is safe at oral doses, and stopping doesn't expose you to anything. The stakes are money, attention, and the quiet calibration of your own bullshit detector.

Year one: $80 leaves your account quietly, and the morning scoop becomes a piece of furniture in your routine. Nobody around you notices, including you. Year three: that's $250, and the version of you that picked it up has done the same with three or four other tubs based on the same mechanism move — the podcast guest says "gut barrier" and you don't notice you're being sold to. Year ten: a few thousand dollars and a cabinet full of mostly-empty containers, and the harder cost — the trained-in reflex to defer to anyone who can recite a plausible mechanism. The people around you start to treat your supplement opinions with the same indulgent quiet they reserve for someone's astrology, which is honest of them.

The version that fades is not your health — it's the part of you that asks but did it actually work in the trial before reaching for the credit card.

What changes if you close the tab

Most of the payoff lands immediately, because the substance wasn't doing anything to take away.

Week one. Eighty dollars a year doesn't leave your account anymore. The morning routine has one fewer step that did nothing. The shelf has one fewer tub.

Month three. The next time a podcast guest says "leaky gut" and "tight junctions" in the same paragraph, you hear the move — you know the trial those words are hanging off was in 106 people with a specific post-infection diagnosis and a documented permeability lab, not in someone tired and a bit bloated. You don't bite. That reflex generalises: the next supplement that gestures at a mechanism without a trial in your population gets the same treatment.

Year three. The cumulative savings — across glutamine and the three other tubs the same instinct kept you from buying — pay for something that actually works. A creatine habit that did move a lift. A standing-desk situation that fixed the back pain. A handful of extra hours of sleep a week because you stopped doomscrolling Reddit at midnight looking for an edge. The friend who recommended the glutamine still buys it; you notice he hasn't changed.

And the smaller, sharper payoff for the readers in the indicated populations: the sickle cell patient walks into the next appointment and asks specifically about Endari. The person whose IBS started after a stomach bug a year ago asks for the lactulose/mannitol test and brings up the Zhou trial. They don't keep walking past their own medicine.

Adjacent entries worth a look: creatine monohydrate (the supplement with the strongest healthy-adult evidence base, and roughly the same price), whey protein (already supplies most of the bound glutamine your diet delivers), the low-FODMAP diet (broader IBS evidence base than glutamine), and the hydroxyurea / voxelotor sickle cell treatments that sit alongside Endari in the modern protocol.

Substance and claimed effects

L-glutamine is the most abundant free amino acid in the human body — roughly 60% of the free amino acid pool in skeletal muscle and 20% of circulating plasma amino acids Cruzat et al. 2018. The body synthesises it endogenously (chiefly in skeletal muscle and lungs), classifying it as non-essential under normal conditions but conditionally essential during severe catabolic stress — burn injury, sepsis, major trauma, prolonged starvation — where demand exceeds synthesis and plasma glutamine drops sharply Lacey & Wilmore 1990. As a supplement, marketed claims cluster around four consequences: (a) repair of intestinal-barrier (leaky gut) integrity; (b) preservation of immune function during heavy training or illness; (c) attenuation of skeletal-muscle catabolism and improved recovery around training; (d) reduction of acute pain crises in sickle cell disease (the one FDA-approved indication, branded as Endari, 2017). This entry covers the substance holistically — all four claims — while honestly flagging that the evidence base is heavily population-dependent: strong for sickle cell and for post-infectious IBS with measurable hyperpermeability, equivocal for critically ill ICU populations, and largely negative for healthy resistance-trained adults.

Evidence by addressing question

Mechanism

Enterocyte fuel. Glutamine is the preferred metabolic substrate for rapidly dividing cells of the small-intestinal mucosa — enterocytes oxidise it in preference to glucose, deriving the majority of their ATP from glutamine catabolism via glutaminolysis Kim & Kim 2017. In vitro and rodent work shows glutamine deprivation rapidly disrupts tight-junction proteins (occludin, claudin-1, ZO-1) and that supplementation restores barrier function via activation of PI3K/Akt signalling pathways Rao & Samak 2012. This is the strongest mechanistic story for the substance — gut barrier integrity in catabolic states is the textbook indication.

Immune-cell fuel. Lymphocytes, macrophages, and neutrophils consume glutamine at rates comparable to glucose during proliferation and reactive-oxygen-species production; in vitro glutamine deprivation impairs lymphocyte mitogenesis and neutrophil bactericidal activity Cruzat et al. 2018. Plasma glutamine drops ~20% after prolonged endurance exercise (marathon, ultramarathon) and remains depressed for several hours, generating the glutamine hypothesis of exercise immunology — that this dip explains post-exercise upper-respiratory-tract infections (URTI) Castell et al. 1996. Empirically, the hypothesis hasn't held — see Evidence below.

Sickle cell mechanism. Sickle erythrocytes have elevated oxidative stress; glutamine is a precursor to NAD⁺/NADH and glutathione, both load-bearing antioxidants. Supplementation increases the ratio of NAD redox in sickle red cells, which is the mechanistic basis for the Endari indication Niihara et al. 2018.

Muscle / anti-catabolic mechanism. Plasma glutamine drops during catabolic illness as muscle exports it; the theory is that exogenous supply spares endogenous protein. Mechanism is plausible in burn / sepsis / TPN populations; far less so in healthy lifters whose plasma glutamine doesn't sustainably drop and whose protein intake is already adequate Wilkinson et al. 2006.

Evidence

Sickle cell disease — strong. The pivotal phase-3 RCT (n=230, 48 weeks, 0.3 g/kg twice daily) reported a median of 3 pain crises in the glutamine arm vs 4 in placebo (25% relative reduction, p=0.005), with a median 6.5-day reduction in cumulative hospitalisation Niihara et al. 2018. This trial supported FDA approval of L-glutamine oral powder (Endari) in July 2017 for patients aged 5 and older FDA 2017.

Post-infectious IBS with hyperpermeability — strong for the subset. A randomised, double-blind, placebo-controlled trial (n=106, 8 weeks, 5 g three times daily) in adults with diarrhoea-predominant IBS following an enteric infection and elevated baseline intestinal permeability reported a ≥50-point drop in IBS Severity Scoring System in 79.6% of the glutamine arm vs 5.8% on placebo, plus normalisation of the lactulose/mannitol ratio Zhou et al. 2019. The trial is single-centre and the entry criteria narrow (post-infectious IBS-D with documented leaky gut) — not generalisable to all IBS.

Critically ill ICU — mixed to harmful at high doses. The REDOXS trial (n=1223, multi-centre RCT) gave critically ill patients with multi-organ failure parenteral plus enteral glutamine at ~0.78 g/kg/day combined; 28-day mortality was non-significantly higher in the glutamine arm (32.4% vs 27.2%, p=0.05) and 6-month mortality significantly higher (43.7% vs 37.2%, p=0.02) Heyland et al. 2013. MetaPlus showed similar signals — higher 6-month mortality in medical-ICU subgroups receiving immune-modulating enteral nutrition (which included glutamine) van Zanten et al. 2014. The Cochrane review concludes glutamine does not reduce mortality or infection in critically ill adults and may increase mortality in subsets with multi-organ failure Tao et al. 2014. Earlier meta-analyses of parenteral glutamine in stable surgical / TPN populations had shown reduced infection rates and shorter length of stay Bollhalder et al. 2013; the modern picture is that the benefit is real for stable surgical / burn / parenteral-nutrition populations but lost or reversed in the sickest, multi-organ-failure ICU patients.

Healthy resistance-trained adults — negative. Candow et al. randomised 31 young adults to 0.9 g/kg lean mass/day glutamine vs maltodextrin during a 6-week resistance training program; no differences in lean mass, strength (1RM squat, bench), or muscle protein degradation Candow et al. 2001. Antonio et al., acutely, found 0.3 g/kg glutamine pre-workout had no effect on weightlifting performance (reps to failure at 2RM intensity) Antonio et al. 2002. Wilkinson et al. showed glutamine added to essential amino acids + carbohydrate did not enhance post-exercise muscle protein synthesis vs EAA+CHO alone Wilkinson et al. 2006. A 2019 systematic review and meta-analysis of glutamine in athletic populations concluded no significant effect on body composition, strength, fatigue, or markers of muscle damage Ramezani Ahmadi et al. 2019. Legault et al. did report attenuated soreness and faster strength recovery after eccentric knee-extension damage at 0.3 g/kg/day for 72 hours post-exercise — a single small (n=16) trial with a narrow endpoint Legault et al. 2015.

Exercise immunity — negative. Castell's original cohort (n=151) reported lower self-reported URTI in marathon/ultra runners given 5 g post-event glutamine vs placebo (19% vs 51%) Castell et al. 1996, but subsequent better-controlled work failed to replicate — Krzywkowski et al. found no effect of glutamine on the post-exercise salivary IgA drop Krzywkowski et al. 2001, and Gleeson's 2008 review concluded the glutamine hypothesis of exercise immunology is not supported by interventional trials Gleeson 2008.

Protocol

Dose ranges in the literature span two orders of magnitude depending on the indication:

Sickle cell (FDA-labelled): 0.3 g/kg twice daily oral, indefinitely; max 30 g/day Niihara et al. 2018.
Post-infectious IBS-D with hyperpermeability: 5 g three times daily for 8 weeks Zhou et al. 2019.
Healthy adult supplementation (consumer market): typically 5–10 g/day as powder, single or split dose, often around training. No clinically endorsed dose for this indication because the indication itself isn't validated.
Critical care (parenteral, hospital): historically 0.3–0.5 g/kg/day IV; current ASPEN/ESPEN guidance has retreated from routine use in multi-organ-failure ICU patients Tao et al. 2014.

Onset varies by indication. Sickle cell trial saw separation from placebo by week 12; IBS-D trial saw symptom relief over 8 weeks; gut barrier markers normalise within 4–8 weeks in animal models.

Contraindications

Glutamine is generally safe at oral doses up to ~30 g/day in healthy adults; pharmacokinetic and safety studies show no consistent adverse effects on liver function, renal function, or ammonia metabolism at these doses Garlick 2001. Real contraindications cluster around catabolic and metabolic-failure states:

Severe hepatic failure / cirrhosis: glutamine is metabolised to glutamate and ammonia; in cirrhosis the ammonia-handling capacity is impaired and supplementation may precipitate or worsen hepatic encephalopathy.
Severe renal failure: impaired urea-cycle clearance; clinical concern though not a hard contraindication in stable CKD.
Critically ill with multi-organ failure: REDOXS-style harm signal Heyland et al. 2013; current consensus avoids high-dose glutamine in this population.
Reye-like syndromes, urea cycle disorders: theoretical risk of hyperammonaemia.
Pregnancy / breastfeeding: no controlled human data; conventional caution.

Misconceptions

"Plasma glutamine drops with exercise, so I should replace it." The drop is real (~20% after a marathon) but is not the cause of post-exercise immunosuppression; supplementing back to baseline doesn't restore lymphocyte function or reduce URTI in controlled trials Gleeson 2008, Krzywkowski et al. 2001. The mechanism the marketing relies on isn't doing the work the marketing implies.

"Glutamine prevents muscle breakdown." True in burn / sepsis / TPN catabolic states; not demonstrated in healthy resistance-trained adults consuming adequate protein Wilkinson et al. 2006, Ramezani Ahmadi et al. 2019. Whey protein already supplies abundant glutamine residues (~5–6% by mass); a healthy lifter's free-glutamine pool is not the rate-limiting factor.

"Glutamine heals leaky gut." Genuine in documented intestinal hyperpermeability (post-infectious IBS-D, chemotherapy mucositis, animal models of colitis) — but the supplement industry sells it for "leaky gut syndrome" as a general wellness construct that itself lacks consensus diagnostic criteria. The Zhou trial enrolled only patients with elevated lactulose/mannitol ratios and post-infectious onset; readers with vague gut complaints aren't the trial population.

Audience

Effect size varies dramatically by population. The narrow groups with real evidence:

Sickle cell disease patients (FDA-approved indication).
Post-infectious IBS-D with documented hyperpermeability.
Burn patients (historic guideline support).
Stable surgical / parenteral-nutrition populations (older meta-analytic signal of reduced infection / length of stay) Bollhalder et al. 2013.
Chemotherapy-induced mucositis (suggestive evidence; not covered in detail here).

Healthy resistance-trained adults and recreational endurance athletes are the population the supplement industry targets, and they're also the population for whom the evidence is most consistently negative.

Alternatives

For each evidenced indication, alternatives outperform or compete:

Gut barrier / IBS: low-FODMAP diet (stronger evidence base in general IBS), soluble fibre, treatment of underlying SIBO or post-infectious dysbiosis.
Muscle preservation / recovery: adequate total protein (~1.6 g/kg/day), creatine monohydrate (catalogue entry), sleep, programming.
Immune support around training: sleep, periodised training load, adequate calories and protein, vitamin D if deficient.
Sickle cell: hydroxyurea, voxelotor, crizanlizumab — all with their own evidence bases.

Failure-modes

Why healthy lifters routinely report no felt effect from glutamine:

Dietary protein already supplies abundant glutamine (whey is ~5–6% glutamine residues; meat ~4–8%); a 150 g/day protein diet already delivers ~10 g of bound glutamine. Adding 5–10 g free glutamine is a small marginal change against this background.
The rate-limiting variable in healthy lifters' recovery is not free-amino-acid availability — it's training stimulus, sleep, total energy balance, and total protein. Adding glutamine doesn't move the bottleneck.
Splanchnic first-pass extraction is high — much of an oral glutamine bolus is consumed by the gut itself before reaching systemic circulation, so the dose that "reaches the muscle" is a fraction of what's swallowed Gleeson 2008.

Practicalities

Bulk L-glutamine powder is commodity-priced — a 1 lb (454 g) tub typically retails $15–25, which at 5 g/day is roughly 3 months of supply (≈ $60–100/year at consumer-grade pricing). For sickle cell, the branded Endari formulation costs vastly more — list pricing has been reported in the $40,000+/year range, almost always insurance-mediated. Generic L-glutamine powder is the same molecule but FDA approval rides on the branded product.

Stakes

The substance's absence has no observable consequence in the healthy general population — plasma glutamine homeostasis is maintained by muscle synthesis. The relevant stakes are economic and opportunity-cost: continued spending on a supplement with negative trials in the user's actual population, and displacement of attention from interventions that would actually move the needle (sleep, total protein, training programming, dietary fibre). In specific clinical populations (untreated sickle cell, post-infectious IBS-D), missing a real indication is the substantive stakes.

Payoff

For the narrow indicated populations, payoff is concrete and trial-anchored: ≈25% reduction in sickle pain crises Niihara et al. 2018; symptom relief in 80% of post-infectious IBS-D with hyperpermeability over 8 weeks Zhou et al. 2019. For the general supplement-taking population, the honest payoff of stopping is the money and shelf space back.

Out-of-scope

Related entries the reader may want: creatine (the supplement with the strongest healthy-adult evidence base), whey protein (the protein source already supplying glutamine), low-FODMAP diet (the IBS intervention with broader evidence), hydroxyurea / voxelotor (the standard-of-care sickle cell medications).

The credibility range

Optimist case

Glutamine is the most abundant free amino acid in the body, mechanistically central to enterocyte function, immune cell metabolism, and antioxidant defense. It is conditionally essential — the body cannot synthesise enough during severe catabolic stress. It has an FDA-approved indication backed by a randomised phase-3 trial Niihara et al. 2018, a positive trial in post-infectious IBS-D with hyperpermeability Zhou et al. 2019, decades of clinical use in burn / surgical / TPN populations with meta-analytic support for reduced infections and length of stay Bollhalder et al. 2013, and a coherent mechanistic story for gut-barrier and immune effects Kim & Kim 2017, Cruzat et al. 2018. Community signal among lifters and biohackers is consistent (decades of word-of-mouth use), safety profile is excellent at oral doses up to 30 g/day Garlick 2001, and cost is trivial. For the readers in any of the indicated populations, supplementation is a real-medicine call.

Skeptic case

For the consumer market the supplement is actually sold into — recreationally training adults wanting recovery, immunity, or "gut health" — controlled trials are consistently negative. Resistance-training trials show no effect on lean mass, strength, or protein balance Candow et al. 2001, Wilkinson et al. 2006; the 2019 meta-analysis confirms Ramezani Ahmadi et al. 2019. The exercise-immunity hypothesis didn't replicate Gleeson 2008, Krzywkowski et al. 2001. The "leaky gut" pitch generalises a narrow post-infectious IBS-D finding into a wellness category whose diagnostic criteria are themselves contested. The high-dose ICU trial showed harm at the catabolic-illness extreme the marketing borrows mechanism from Heyland et al. 2013. Splanchnic first-pass extraction means most of an oral dose is consumed by the gut, so the systemic delivery the marketing implies is overstated. Dietary protein at adequate intakes already supplies abundant glutamine residues — supplementation adds a small marginal fraction against that background. Commercial incentive is large (it's a commodity sold at high consumer markup).

Author's call

The substance has two faces. As a prescription-grade therapeutic in two narrow indications (sickle cell disease; post-infectious IBS-D with documented hyperpermeability) it is genuine medicine backed by phase-3 RCT data. As a general wellness supplement for healthy adults around training, illness prevention, or "gut health" it is overhyped — the mechanism marketing leans on doesn't translate to felt effect in controlled trials. The article scores evidence at 2 (sparse and contested in the supplement's actual consumer use-case, with stronger pockets in clinical populations), health_short_term at 2 (real but population-narrow), and treats the entry as a decide: most readers don't need it; readers in the narrow indications should talk to a clinician about the actual FDA-approved or trial-supported protocol rather than picking a consumer tub. controversy sits in the moderate band — clinical use is contested, the consumer use is not strongly defended by anyone serious. The entry leans skeptic-with-named-exceptions; it doesn't dismiss the substance, but it refuses to inherit the marketing.

Stakeholder and incentive map

Supplement industry (pro): bulk L-glutamine is a commodity sold at consumer markup; nearly every major sports-supplement brand carries it. Marketing copy borrows the clinical mechanism (gut barrier, immune fuel) without distinguishing the clinical from the general population.
Pharmaceutical (pro, narrow): Emmaus Medical (Endari) has commercial incentive in the sickle-cell indication, where the molecule is real medicine.
Clinical nutrition guidelines (mixed): ASPEN and ESPEN have retreated from routine glutamine recommendation in critically ill ICU patients post-REDOXS, while still supporting it in burn and stable surgical populations. The clinical guidance picture is honestly moderating.
Sports-nutrition academic community (skeptical): ISSN / Gleeson lineage has been consistently skeptical of the lifter / athlete claims since the mid-2000s; the 2019 meta-analysis is the current canonical summary.
"Gut health" / functional medicine community (pro, often beyond evidence): heavy promotion in the leaky-gut wellness market, frequently extrapolating from animal and post-infectious IBS data to general "intestinal repair" protocols.

Population variability

Sickle cell disease: meaningful effect on pain crises; FDA-labelled Niihara et al. 2018.
Post-infectious IBS-D with documented hyperpermeability: large effect on symptom severity Zhou et al. 2019. Effect not validated in IBS-C, non-post-infectious IBS, or general functional gut complaints.
Burn / major surgical / TPN populations: historic clinical signal of reduced infections and length of stay; effect smaller in modern critical care with otherwise-optimised nutrition Bollhalder et al. 2013.
Critically ill with multi-organ failure: harm signal at high doses Heyland et al. 2013; current consensus avoids the population.
Healthy resistance-trained / endurance adults: no demonstrated benefit on performance, body composition, recovery, or immunity in controlled trials Ramezani Ahmadi et al. 2019, Gleeson 2008.
Chemotherapy-induced mucositis: suggestive effect on incidence and severity (out-of-scope for this entry but flagged in editor notes for separate coverage).
Sex and age: no consistent differential effect documented. The narrow-indication trials enrolled mixed populations.

Knowledge gaps

No large RCT testing glutamine for "leaky gut syndrome" as defined in the wellness market — only the narrow post-infectious IBS-D trial.
No definitive trial in IBD (Crohn's, ulcerative colitis) showing benefit despite plausible mechanism; small trials have been negative or null.
No long-term safety data beyond ~1–2 years of continuous high-dose use.
Limited head-to-head against alternative gut-barrier interventions (zinc carnosine, butyrate, low-FODMAP).
The splanchnic first-pass extraction question — what fraction of an oral dose reaches systemic circulation in different metabolic states — is incompletely characterised.
What would change the call: a well-powered RCT in healthy resistance-trained adults with composition and recovery endpoints; a multi-centre replication of Zhou 2019 in broader IBS populations.

Scope vs brief. The brief named gut lining integrity, immune recovery, and muscle preservation as the consequences worth covering. The entry covers all three, but lands honestly on each: gut barrier is real in a narrow trial population (post-infectious IBS-D with documented hyperpermeability) and overhyped everywhere else; immune recovery in athletes did not replicate after the original Castell 1996 result; muscle preservation is genuine in catabolic clinical states but null in healthy resistance-trained adults. Adding the fourth real consequence — sickle cell pain crises (FDA-approved 2017) — was necessary for honest holistic coverage; the brief didn't name it but the substance has one phase-3 RCT to its name and it would be dishonest to omit.

Action choice. Toss-up between know and decide. Landed on decide because there's a genuine tradeoff for two narrow populations (sickle cell, post-infectious IBS-D with permeability) — those readers should weigh it with a clinician, not just be aware of it. For the wider audience the action collapses to "no", which the article delivers as the honest default.

Score difficulties. health_short_term sat between 1 and 2 — net-zero across the bulk readership but a substantial population-narrow win. Landed on 2 because the sickle cell and Zhou IBS-D effects are large where they apply, and the spec calls for holistic scoring across the substance, not weighted by the population fraction (that's what applicability is for). controversy at 2 reflects moderate field disagreement: clinical guidance has genuinely retreated post-REDOXS, but the consumer-side marketing is more uncontested-by-default than actively defended; nobody serious is fighting for the gym-shelf use case, but the gym-shelf use case persists.

Excluded scope. Chemotherapy-induced mucositis (suggestive but not strong; pediatric and adult evidence diverges); inflammatory bowel disease (Crohn's, ulcerative colitis — plausible mechanism, mostly negative or null small trials); HIV-associated wasting (older literature, not modern standard-of-care); glutamine-loading for ammonia-cycle modulation in specific metabolic disorders (specialist-clinician scope). Each could warrant its own narrow entry; flagged for backlog.

Separate-entry candidates.

Endari (L-glutamine for sickle cell) — could be its own entry under medical or a sickle-cell-management cluster, since the dosing, prescription dynamics, and population are fully distinct from the supplement use case.
Leaky gut syndrome as a wellness construct — meta-entry on the diagnostic-criteria gap and the supplement market built around it. Glutamine, zinc carnosine, butyrate all hang off it.
Post-infectious IBS — a real clinical entity distinct from primary IBS, with its own evidence base and treatment angles (rifaximin, the Zhou glutamine protocol, low-FODMAP).

Future links. Should cross-link to creatine, whey protein, low-FODMAP, and a future Endari / sickle-cell-management entry once written. related on meta currently points at creatine and whey-protein; will need updating as the catalogue grows.

Dream narrative choice. Overall score ~9, well below the 40 obligatory threshold, but a relief-lever narrative was warranted — the honest payoff here is money and bullshit-detector calibration back, plus pointing the narrow indicated populations at their real medicine. Used the relief lever explicitly per dream-narrative.md §3, not an aspiration lever (which would have rung false).